Skip to main content
LGND
NASDAQ Life Sciences

Ligand Files XOMA Financials: $886M Deal Shows $142M Goodwill, $41M H1 Loss

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$286.92
Mkt Cap
$5.72B
52W Low
$161.82
52W High
$326.63
52W Position info
77% above low
Off High info
12% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

LGND sits 77% above its 52-week low of $161.82.

Summary

Ligand's 8-K/A provides the first detailed financials for its XOMA Royalty acquisition, revealing XOMA's $41.2M H1 loss and the $886M purchase price allocation, including $142M in goodwill.


Key Events · M&A and Partnerships · LGND

  • XOMA H1 2026 Financials Disclosed

    XOMA Royalty reported a net loss of $41.2 million for the six months ended June 30, 2026, including $19.7 million in credit losses on Daré receivables and $23.6 million in impairment charges.

  • Purchase Price Allocation Revealed

    Estimated net purchase consideration was $886.2 million, with preliminary goodwill of $142.4 million and identified intangible assets of $97.6 million across 8 programs.

  • Pro Forma Combined Results

    Pro forma combined net income was $17.9 million for H1 2026 and $139.6 million for full-year 2025, reflecting the merger as if completed January 1, 2025.

  • Financing and Debt Repayment

    The acquisition was funded with $700 million in 0% convertible notes issued June 25, 2026, plus cash; Ligand repaid XOMA's $114.6 million Blue Owl loan and redeemed $68.6 million in preferred stock.


Analysis · LGND · Life Sciences

This amendment delivers the first hard look at XOMA Royalty's standalone financials and the combined pro forma picture since the July 14 merger closed. XOMA lost $41.2 million in the first half of 2026, driven by a $19.7 million write-off of Daré receivables and $23.6 million in impairment charges tied to failed clinical programs. Ligand paid an estimated $886 million in net consideration, booking $142 million in goodwill and $97.6 million in identified intangible assets. The pro forma statements show the combined company would have earned $17.9 million in H1 2026 and $139.6 million in 2025, giving investors their first concrete view of the deal's earnings impact.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LGND was trading at $286.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $161.82 to $326.63. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LGND - Latest Insights

LGND
Oct 30, 2026, 4:47 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $324.00
Real-time Price: $308.70 info
Change: -$15.30 (-5%) info
Market Cap: $6.177B info
LGND
Oct 29, 2026, 3:12 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $316.21
Real-time Price: $308.70 info
Change: -$7.51 (-2%) info
Market Cap: $6.177B info
LGND
Oct 29, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $311.87
Real-time Price: $308.70 info
Change: -$3.17 (-1%) info
Market Cap: $6.177B info
LGND
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $311.87
Real-time Price: $308.70 info
Change: -$3.17 (-1%) info
Market Cap: $6.177B info
LGND
Sep 24, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $298.41
Real-time Price: $308.70 info
Change: +$10.29 (+3%) info
Market Cap: $6.177B info